Latest Indonesia News

PT ANTAM (Persero) Tbk (ASX:ATM, IDX:ANTM) delivered stronger nine-month 2026 operating volumes across gold, ferronickel, bauxite and alumina, while advancing Indonesia’s battery and mineral-processing agenda. The unaudited report also details Rp5.05 trillion in dividends, but provides no nine-month revenue or profit figures.

Range International sharply reduced its quarterly cash outflow while lifting pallet volumes and building a larger rental fleet. But the next phase still depends on a partly subscribed entitlement offer, external funding and several customer opportunities that remain indicative.

ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.

Bass Oil’s September-quarter production rose 21% to 23,944 barrels after Bunian 6 came online, while sales revenue reached A$2.82 million. Cash fell to A$2.07 million as drilling and development spending continued, leaving the company with an estimated two quarters of funding under its Appendix 5B calculation.

Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.

Nickel Industries delivered US$125.9 million of adjusted EBITDA in the September quarter, led by a second consecutive record from the Hengjaya Mine. Its new ENC HPAL project reached 50% of nameplate capacity, but severe dry conditions delayed the next step: commercial sales.

Recce Pharmaceuticals says a review of blinded Phase 3 data for its RECCE 327 Gel showed strong efficacy and a positive safety profile. An independent committee is expected to assess unblinded data from 75 patients as soon as mid-November, while recruitment continues.

Cue Energy delivered $19.8 million in operating cash flow and maintained its dividend in FY2026, despite lower profit, shrinking reserves and asset impairments. With Horizon Oil now controlling 57.03% of the register, the company enters FY2027 with a new board and an unusually busy drilling schedule.

Firebrick Pharma has secured Philippine marketing approval for Nasodine Nasal Spray as an over-the-counter antiseptic, opening a potential launch in the 116 million-person market from early 2027. The approval remains subject to post-approval documentation and future revalidation.

Bass Oil’s September revenue surged to A$1.69 million as Bunian 6 drove a sharp increase in Indonesian production and Cooper Basin sales resumed. The company is now targeting first gas from Vanessa by year end, subject to regulatory approval and remaining site work.

Range International has given shareholders an extra 10 days to participate in its 1-for-1 entitlement offer, while leaving the $0.09 issue price and approximately $1.69 million target unchanged. The revised timetable puts the focus on participation levels and any shortfall after the offer closes.

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.